In vivo studies have demonstrated that OS patients exhibit enhanced anti-tumor activity of cytotoxic T cells following treatment with CTLA-4 antibodies, revealing the potential of CTLA-4 inhibitors in the treatment of OS [24]. The gene discussed is CTLA4; the disease is neoplasm.